NKTR Nektar Therapeutics

Price (delayed)

$0.7163

Market cap

$136.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$193.02M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
Nektar Therapeutics's EPS has increased by 36% YoY and by 4.3% QoQ
The net income has grown by 35% year-on-year and by 4.3% since the previous quarter
Nektar Therapeutics's quick ratio has decreased by 11% from the previous quarter but it has increased by 8% YoY
Nektar Therapeutics's equity has shrunk by 61% YoY and by 19% QoQ
The gross profit has declined by 24% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
190.77M
Market cap
$136.65M
Enterprise value
$193.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
1.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
Earnings
Revenue
$88.26M
EBIT
-$265.02M
EBITDA
-$255.68M
Free cash flow
-$189.96M
Per share
EPS
-$1.56
Free cash flow per share
-$1
Book value per share
$0.84
Revenue per share
$0.46
TBVPS
$2.32
Balance sheet
Total assets
$442.24M
Total liabilities
$282.88M
Debt
$121.29M
Equity
$159.37M
Working capital
$346.91M
Liquidity
Debt to equity
0.76
Current ratio
7.66
Quick ratio
7.19
Net debt/EBITDA
-0.22
Margins
EBITDA margin
-289.7%
Gross margin
62.9%
Net margin
-332.7%
Operating margin
-320.2%
Efficiency
Return on assets
-53.2%
Return on equity
-121.9%
Return on invested capital
-49.9%
Return on capital employed
-67.9%
Return on sales
-300.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-0.51%
1 week
8.37%
1 month
27.91%
1 year
-48.09%
YTD
26.78%
QTD
26.78%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$88.26M
Gross profit
$55.54M
Operating income
-$282.64M
Net income
-$293.67M
Gross margin
62.9%
Net margin
-332.7%
The operating income is up by 35% year-on-year and by 3.2% since the previous quarter
The net income has grown by 35% year-on-year and by 4.3% since the previous quarter
The net margin has increased by 30% YoY and by 4.9% QoQ
The operating margin has grown by 30% YoY and by 3.8% from the previous quarter

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
0.85
P/S
1.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
Nektar Therapeutics's EPS has increased by 36% YoY and by 4.3% QoQ
The P/B is 64% below the 5-year quarterly average of 2.4 but 23% above the last 4 quarters average of 0.7
Nektar Therapeutics's equity has shrunk by 61% YoY and by 19% QoQ
The stock's P/S is 92% less than its 5-year quarterly average of 18.5 and 30% less than its last 4 quarters average of 2.2
The revenue has contracted by 7% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has decreased by 45% YoY and by 21% from the previous quarter
Nektar Therapeutics's return on sales has increased by 33% YoY and by 5% QoQ
NKTR's ROA is down by 11% YoY and by 10% from the previous quarter
The return on invested capital has declined by 4.8% since the previous quarter

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 56% more than its total liabilities
Nektar Therapeutics's total assets has decreased by 43% YoY and by 11% from the previous quarter
The total liabilities has contracted by 23% YoY and by 4.9% from the previous quarter
The debt is 24% lower than the equity
The debt to equity has soared by 130% YoY and by 21% QoQ
Nektar Therapeutics's equity has shrunk by 61% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.